Gebelikte Hipertiroidizm; Klinik Bulgular, Tanı ve Tedavi
Özet
Gebelikte hipertiroidizm, hem anne hem de fetüs için önemli sağlık sorunlarına yol açabilen bir durumdur. Belirgin hipertiroidizm, düşük tiroid uyarıcı hormon (TSH) seviyeleri ile birlikte serbest tiroksin (T4) ve/veya triiyodotironin (T3) seviyelerinin artışıyla karakterizedir.
Gebelikte hipertiroidizmin en yaygın nedeni, uyarıcı antikorların TSH reseptörlerini hedef alarak aşırı tiroid aktivitesine yol açtığı bir otoimmün bozukluk olan Graves hastalığıdır. Ek olarak, insan koryonik gonadotropinin (hCG) tiroid üzerindeki uyarıcı etkisi, hiperemesis gravidarum ve gebelikte geçici tirotoksikoz gibi durumlarda geçici hipertiroidizme yol açabilir.
Hipertiroidizmin klinik belirtileri arasında taşikardi, sinirlilik, terleme, nefes darlığı, tremor, ısıya tahammülsüzlük, barsak hareketlerinde artış ve hipertansiyon bulunur. Bu belirtiler, normal gebelikte ortaya çıkan semptomlarla karışabildiğinden, dikkatli değerlendirme gereklidir.
Tedavi edilmemiş belirgin hipertiroidizm, spontan abortus, erken doğum, düşük doğum ağırlığı, ölü doğum, preeklampsi ve kalp yetmezliği gibi olumsuz maternal ve yenidoğan sonuçları ile ilişkilidir. Tanı, düşük TSH ve yüksek serbest T4 düzeylerinin saptanması ile konur. Tedavide temel amaç, fetal veya neonatal hipotiroidiye neden olmadan maternal hipertiroidizmi kontrol altına almaktır.
Sonuç olarak, gebelikte hipertiroidizmin erken tanı ve uygun tedavisi, hem anne hem de fetüsün sağlığı için kritik öneme sahiptir.
Hyperthyroidism during pregnancy is a condition that can lead to significant health complications for both the mother and the fetus. Overt hyperthyroidism is characterized by suppressed thyroid-stimulating hormone (TSH) levels accompanied by elevated free thyroxine (T4) and/or triiodothyronine (T3) concentrations.
The most prevalent cause of hyperthyroidism in pregnancy is Graves' disease, an autoimmune disorder wherein stimulatory antibodies target TSH receptors, resulting in excessive thyroid activity. Additionally, the stimulatory effect of human chorionic gonadotropin (hCG) on the thyroid can lead to transient hyperthyroidism in conditions such as hyperemesis gravidarum and gestational transient thyrotoxicosis.
Clinical manifestations of hyperthyroidism include tachycardia, nervousness, excessive sweating, dyspnea, tremors, heat intolerance, increased bowel movements, and hypertension. These symptoms can overlap with normal physiological changes in pregnancy, necessitating careful clinical evaluation.
Untreated overt hyperthyroidism is associated with adverse maternal and neonatal outcomes, such as spontaneous abortion, preterm birth, low birth weight, stillbirth, preeclampsia, and heart failure. Diagnosis is confirmed through laboratory findings of decreased TSH and elevated free T4 levels. The primary therapeutic objective is to manage maternal hyperthyroidism without inducing fetal or neonatal hypothyroidism.
In conclusion, early diagnosis and appropriate management of hyperthyroidism during pregnancy are crucial to safeguarding the health of both mother and fetus.
Referanslar
Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010; 31:702.
Lee SY, Pearce EN. Assessment and treatment of thyroid disorders in pregnancy and the postpartum period. Nat Rev Endocrinol. 2022;18(3):158-171. doi:10.1038/s41574-021-00604-z
Davis LE, Lucas MJ, Hankins GD, et al. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 1989; 160:63.
Sheffield JS, Cunningham FG. Thyrotoxicosis and heart failure that complicate pregnancy. Am J Obstet Gynecol 2004; 190:211.
Phoojaroenchanachai M, Sriussadaporn S, Peerapatdit T, et al. Effect of maternal hyperthyroidism during late pregnancy on the risk of neonatal low birth weight. Clin Endocrinol (Oxf) 2001; 54:365.
Millar LK, Wing DA, Leung AS, et al. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol 1994; 84:946.
Kriplani A, Buckshee K, Bhargava VL, et al. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol 1994; 54:159.
Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol 2013; 1:238.
Salvi M, How J. Pregnancy and autoimmune thyroid disease. Endocrinol Metab Clin North Am 1987; 16:431.
Kung AW, Lau KS, Kohn LD. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy. J Clin Endocrinol Metab 2001; 86:3647.
Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017; 27:315.
Vos XG, Smit N, Endert E, et al. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol (Oxf) 2008; 69:311.
Ota H, Amino N, Morita S, et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin Endocrinol (Oxf) 2007; 67:41.
Glinoer D, de Nayer P, Bourdoux P, et al. Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 1990; 71:276.
Goodwin TM, Montoro M, Mestman JH, et al. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 1992; 75:1333.
Yamazaki K, Sato K, Shizume K, et al. Potent thyrotropic activity of human chorionic gonadotropin variants in terms of 125I incorporation and de novo synthesized thyroid hormone release in human thyroid follicles. J Clin Endocrinol Metab 1995; 80:473.
Kimura M, Amino N, Tamaki H, et al. Gestational thyrotoxicosis and hyperemesis gravidarum: possible role of hCG with higher stimulating activity. Clin Endocrinol (Oxf) 1993; 38:345.
Hershman JM. Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Thyroid 1999; 9:653.
Momotani N, Noh J, Oyanagi H, et al. Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status. N Engl J Med 1986; 315:24.
Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.
Mortimer RH, Cannell GR, Addison RS, et al. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab 1997; 82:3099.
Roti E, Minelli R, Salvi M. Clinical review 80: Management of hyperthyroidism and hypothyroidism in the pregnant woman. J Clin Endocrinol Metab 1996; 81:1679.
Momotani N, Noh JY, Ishikawa N, Ito K. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab 1997; 82:3633.
Bowman P, Osborne NJ, Sturley R, Vaidya B. Carbimazole embryopathy: implications for the choice of antithyroid drugs in pregnancy. QJM 2012; 105:189.
Di Gianantonio E, Schaefer C, Mastroiacovo PP, et al. Adverse effects of prenatal methimazole exposure. Teratology 2001; 64:262.
Johnsson E, Larsson G, Ljunggren M. Severe malformations in infant born to hyperthyroid woman on methimazole. Lancet 1997; 350:1520.
Wilson LC, Kerr BA, Wilkinson R, et al. Choanal atresia and hypothelia following methimazole exposure in utero: a second report. Am J Med Genet 1998; 75:220.
Foulds N, Walpole I, Elmslie F, Mansour S. Carbimazole embryopathy: an emerging phenotype. Am J Med Genet A 2005; 132A:130.
Wing DA, Millar LK, Koonings PP, et al. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol 1994; 170:90.
Clementi M, Di Gianantonio E, Pelo E, et al. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet 1999; 83:43.
Rosenfeld H, Ornoy A, Shechtman S, Diav-Citrin O. Pregnancy outcome, thyroid dysfunction and fetal goitre after in utero exposure to propylthiouracil: a controlled cohort study. Br J Clin Pharmacol 2009; 68:609.
Bowman P, Vaidya B. Suspected Spontaneous Reports of Birth Defects in the UK Associated with the Use of Carbimazole and Propylthiouracil in Pregnancy. J Thyroid Res 2011; 2011:235130.
Yoshihara A, Noh J, Yamaguchi T, et al. Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 2012; 97:2396.
Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 2013; 98:4373.
De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2543.
Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017; 27:315.
Roti E, Minelli R, Gardini E, et al. Controversies in the treatment of thyrotoxicosis. Adv Endocrinol Metab 1994; 5:429.
Kuy S, Roman SA, Desai R, Sosa JA. Outcomes following thyroid and parathyroid surgery in pregnant women. Arch Surg 2009; 144:399.
Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999; 12:541.
Lip GY, Beevers M, Churchill D, et al. Effect of atenolol on birth weight. Am J Cardiol 1997; 79:1436.
Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990; 301:587.
Stoffer SS, Hamburger JI. Inadvertent 131I therapy for hyperthyroidism in the first trimester of pregnancy. J Nucl Med 1976; 17:146.
